ABBV•benzinga•
AbbVie Updates FY22 Adj. EPS Guidance From $14.00-$14.20 To $13.92-$14.12 vs $14.11 Est. To Include Unfavorable Impact Of $0.08/Share Related To Acquired IPR&D And Milestones Expense Incurred
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 29, 2022 by benzinga